Healthcare Services

Global Granulomatosis With Polyangiitis Treatment Industry Trends and Market Growth Forecast for 2026–2030

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Granulomatosis With Polyangiitis Treatment Market By 2030 Starting From Its 2026 Size?

The granulomatosis with polyangiitis treatment market size has experienced robust expansion in recent years. This market is set to increase from $2.55 billion in 2025 to $2.75 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. The historical progression of this market can be linked to heightened autoimmune disease recognition, the accessibility of corticosteroids, specialized hospital nephrology services, the utilization of immunosuppressive drugs, and the uptake of diagnostic imaging.

The granulomatosis with polyangiitis treatment market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $3.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this projected growth include advancements in biologic drugs, the development of precision treatments for autoimmune conditions, improved early diagnostic screening methods, increased need for chronic disease management, and the proliferation of specialty clinics. Key trends expected during this period involve a greater adoption of biologic therapies, a heightened demand for early diagnosis of autoimmune diseases, the development of more extensive strategies for long-term disease remission, an increase in combination immunosuppressive treatments, and enhanced methods for monitoring organ damage.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21196&type=smp

What Primary Drivers Are Shaping The Development Of The Granulomatosis With Polyangiitis Treatment Market?

The growing occurrence of autoimmune diseases is projected to boost the granulomatosis with polyangiitis treatment market in the future. These conditions develop when the body’s immune system incorrectly targets its own healthy cells and tissues, causing inflammation and harm across different organs. The rising incidence of autoimmune diseases stems from environmental factors, including infections, chemicals, or pollutants, alongside evolving lifestyle patterns. Granulomatosis with polyangiitis treatment supports the management of autoimmune conditions through immunosuppressive approaches like corticosteroids and cyclophosphamide. These therapies manage inflammation and avert organ damage, highlighting the importance of timely and personalized treatment for other autoimmune conditions that operate similarly. As an illustration, a June 2023 report from the Office for National Statistics, a UK government body, indicated that the worldwide count of individuals with multiple sclerosis (MS), an autoimmune disorder, reached 2.9 million in 2023, an increase from 2.8 million in 2022. Consequently, the expanding prevalence of autoimmune diseases is fueling the expansion of the granulomatosis with polyangiitis treatment market.

Which Segment Categories Define The Granulomatosis With Polyangiitis Treatment Market?

The granulomatosis with polyangiitis treatment market covered in this report is segmented –

1) By Drug Type: Steroids, Immunosuppressants, Other Drug Types

2) By Route Of Administration: Oral, Intravenous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Steroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone

2) By Immunosuppressants: Cyclophosphamide, Methotrexate, Azathioprine, Mycophenolate mofetil, Rituximab

3) By Other Drug Types: Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG), Biologic Agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Which Upcoming Trends Are Expected To Influence The Granulomatosis With Polyangiitis Treatment Market?

Major companies in the granulomatosis with polyangiitis treatment market are concentrating on developing innovative products, including oral corticosteroids, to offer patients more effective treatment options that improve disease management while minimizing the long-term side effects of steroid use. Oral corticosteroids are medications designed to reduce inflammation and suppress the immune system, frequently utilized in treating allergies, autoimmune diseases, and inflammatory disorders. For instance, in October 2024, AstraZeneca plc, a pharmaceutical company based in the UK, announced that Fasenra (bevacizumab) had been approved in the European Union, a Europe-based political and economic union of European countries, as an add-on therapy for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This approval follows positive results from the MANDARA Phase III trial, which showcased Fasenra’s effectiveness in achieving remission and decreasing reliance on oral corticosteroids in EGPA patients.

Who Are The Top Companies Competing In The Granulomatosis With Polyangiitis Treatment Market?

Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F Hoffmann La Roche Ltd, Sanofi S A, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, ChemoCentryx Inc, Medac Pharma Inc, InflaRx GmbH, AbbVie Inc, Johnson & Johnson, Bristol Myers Squibb Company, Novartis AG, Biogen Inc, Takeda Pharmaceutical Company Limited, UCB S A, Bayer AG, Merck & Co Inc, Eli Lilly and Company, Astellas Pharma Inc

Read the full granulomatosis with polyangiitis treatment market report here:

https://www.thebusinessresearchcompany.com/report/granulomatosis-with-polyangiitis-treatment-global-market-report

How Does The Granulomatosis With Polyangiitis Treatment Market Perform Across Major Global Regions?

North America was the largest region in the granulomatosis with polyangiitis treatment market in 2025. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Granulomatosis With Polyangiitis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21196&type=smp

Browse Through More Reports Similar to the Global Granulomatosis With Polyangiitis Treatment Market 2026, By The Business Research Company

Giant Cell Arteritis Global Market Report

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Nasal Polyps Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/nasal-polyps-treatment-global-market-report

Zoonotic Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/zoonotic-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795